person · intermediate · partly written
Yana Pikman, MD
Pediatric hematologist-oncologist at Dana-Farber Cancer Institute who leads the Pikman Lab on pediatric leukemia.
Also called: Yana Pikman
Position and training as printed
Dana-Farber prints her as Assistant Professor of Pediatrics at Harvard Medical School and Co-Director of the Hematologic Malignancy Program, with an MD from Harvard Medical School, residency in the Boston Combined Residency Program and a pediatric hematology and oncology fellowship at Boston Children's and Dana-Farber. A conflicting page calling her Associate Professor was not accepted over the institute page. 1
Reported, not yet replicated
What her record rests on more
First author of the 2016 MTHFD2 paper in AML, the 2021 LEAP matched-therapy study and the 2022 SHMT1/2 paper in T-ALL; middle or late author on the 2025 to 2026 papers visible in the record. The LEAP study reports feasibility, not response: 17 patients received the matched drug and the paper reports no response rate. 234
Reported, not yet replicated
Public role
Assistant Professor of Pediatrics, Harvard Medical School; Co-Director, Hematologic Malignancy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Affiliation
Dana-Farber Cancer Institute; Harvard Medical School
Works on
Profile URL
Still open here
- What is the year of her first faculty appointment? No page states it.
- Are there doctoral theses from the group in public repositories? None was found; ProQuest and Harvard DASH were not searched in depth.
Linked from
Sources
- Yana Pikman, MD (Dana-Farber physician profile). (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- Pikman Y, et al. Targeting MTHFD2 in acute myeloid leukemia (J Exp Med 2016). (2016). paper; opened 2026-11-17 all records citing this
- Pikman Y, et al. Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium (Cancer Discovery 2021). (2021). paper; opened 2026-11-17 all records citing this
- Pikman Y, et al. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy (Leukemia 2022). (2022). paper; opened 2026-11-17 all records citing this
- Pikman Lab: research (Dana-Farber). (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (3)
This record has been changed 3 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/people/yana-pikman.json